Mendus’s Q226 results highlighted continued execution of its broadened vididencel strategy, with the first eight patients now enroled in the Phase Ib VITAL-CML study and an initial safety, tolerability and early molecular response readout expected in H226.
The planned Phase IIa VITAL-TFR2 study is expected to start in Q426, subject to supportive VITAL-CML interim safety data, with preparations supported by the South Australian Health and Medical Research Institute and leading chronic myeloid leukaemia (CML) and treatment-free remission (TFR) expert, professor Timothy Hughes.
In acute myeloid leukaemia, CADENCE has reached its first 20-patient enrolment milestone, while the Phase Ib DIVA study remains on track to start in H226.
Financially, the Q226 operating loss narrowed 15% y-o-y to SEK20.5m (Q225: SEK24.1m), while operating cash outflow improved to SEK12.5m (Q225: SEK25.7m) and quarter-end gross cash stood at SEK59.9m (net: SEK29.0m).
Management currently provides a cash runway into early 2027 and is evaluating financing alternatives.